お知らせ • May 23
Caris Life Sciences Presents 32 Studies At Asco 2026 Highlighting Advances in Multi-Omic Biomarker Research and Real-World Evidence
Caris Life Sciences, the Caris Precision Oncology Alliance and collaborators from more than 60 institutions will collectively present 32 studies at the 2026 American Society of Clinical Oncology Annual Meeting, including one rapid oral presentation and multiple posters across 10 tumor types as well as pan-cancer analyses. These studies reflect the use of multi-omic biomarker research and real-world data to advance understanding of tumor biology and help inform precision oncology approaches. Highlighted research being presented at the 2026 ASCO Annual Meeting includes breast, colorectal, lung, endometrial and renal cell carcinoma studies, in addition to pan-cancer analyses. These studies are retrospective, real-world analyses and multi-omic biomarker investigations focused on immuno-oncology, tumor microenvironment characterization, and predicting treatment response and resistance. Among the data to be presented are two Caris-led studies evaluating novel biomarker insights. One study examines how genetic ancestry influences ultraviolet (UV)-related mutational signatures in melanoma and their association with immunotherapy response. A second study evaluates ESR1 amplification in breast cancer, identifying it as a distinct genomic subtype associated with reduced survival and decreased benefit from CDK4/6 inhibitor therapies. The 32 studies represent collaborations with cancer centers, academic institutions and research organizations across the United States, Europe, Asia and the Middle East, including Dana-Farber Cancer Institute, Mayo Clinic, Memorial Sloan Kettering Cancer Center and the National Cancer Institute. Clinical impact of MSH3 loss-of-function alterations in patients treated with immune checkpoint blockade across cancer types. (Abstract 10516) Session: Prevention, Risk Reduction, and Genetics. Date/Time: Sunday, May 31, 2026 — 10:51 AM–10:57 AM CDT. Location: S403. Mitochondrial DNA (mtDNA) expression as used to define metabolic and immune states in colorectal cancer (CRC). (Abstract 2647) Session: Developmental Therapeutics—Immunotherapy. Date/Time: Saturday, May 30, 2026, 1:30 PM–4:30 PM CDT. Location: Hall A, Poster: 437. Distinct late recurrence patterns and immune landscape of HER2-positive invasive lobular carcinoma (ILC): Analysis of NCCTG N9831 (Alliance) trial and real-world cohort. (Abstract 564) Session: Breast Cancer—Local/Regional/Adjuvant. Date/Time: Monday, June 1, 2026, 1:30 PM–4:30 PM CDT. Location: Hall A, Poster: 49. Organ- and histology-specific molecular and immune landscape of metastatic breast cancer. (Abstract 1024) Session: Breast Cancer—Metastatic. Date/Time: Monday, June 1, 2026, 1:30 PM–4:30 PM CDT. Location: Hall A, Poster: 138. TP53 status and licensing complex/IFN? transcriptional profiles to stratify endocrine-related outcomes with CDK4/6i exposure in 10,833 real-world ER+/HER2- breast cancers and a treatment-naïve subset. (Abstract 1032) Session: Breast Cancer—Metastatic. Date/Time: Monday, June 1, 2026, 1:30 PM–4:30 PM CDT. Location: Hall A, Poster: 146. Survival outcomes of human epidermal growth factor receptor 2 (HER2)-amplified and HER2-mutated left-sided colorectal cancer (CRC) patients treated with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs). (Abstract 3543) Session: Gastrointestinal Cancer—Colorectal and Anal. Date/Time: Saturday, May 30, 2026, 9:00 AM–12:00 PM CDT. Location: Hall A, Poster: 297. Association of FBXW7 mutation with prolonged survival in microsatellite instability-high colorectal cancer treated with immune checkpoint blockade. (Abstract 3657) Session: Gastrointestinal Cancer—Colorectal and Anal. Date/Time: Saturday, May 30, 2026, 9:00 AM–12:00 PM CDT. Location: Hall A, Poster: 424. Immune microenvironment signatures as prognostic biomarkers in gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC). (Abstract 4180) Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary. Date/Time: Saturday, May 30, 2026, 9:00 AM–12:00 PM CDT. Location: Hall A, Poster: 163. Influence of genetic ancestry on UV mutational signatures linked to immunotherapy response in melanoma, beyond TMB. (Abstract 3087) Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology. Date/Time: Saturday, May 30, 2026, 1:30 PM–4:30 PM CDT. Location: Hall A, Poster: 224. Identification of high-grade neuroendocrine carcinoma (HGNEC) biology across tumor types through transcriptomic profiling and validation in lung cancer. (Abstract 3121) Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology. Date/Time: Saturday, May 30, 2026, 1:30 PM–4:30 PM CDT.